Role of Acetyl CoA carboxylase in type 2 diabetic kidney disease

NIH RePORTER · NIH · R56 · $101,400 · view on reporter.nih.gov ↗

Abstract

Abstract: Background: Our earlier human observational studies showed upregulation of de novo lipogenesis (DNL) linked with upregulation of renal acetyl-CoA carboxylase (ACC) encoding genes ACACA and ACACB in progressors of diabetic kidney disease with type 2 diabetes, suggesting that upregulation of renal DNL might be a mechanism of diabetic kidney disease progression in type 2 diabetes. The goal of this project is to generate a transgenic mouse model with conditional knocked out Acaca and Acacb in podocytes and proximal tubular epithelial cells aimed at testing the preservation of renal function and structural histology in the knocked out in vivo model system compared with the wild type diabetic mouse model in future research subject of R01 grant application. Methods: We will utilize a breeding scheme consisting of cross breeding of ACC1/2 flox mice with podocin-Cre and Pepck-Cre mice all on 129SVE background. Outcome: It is expected that by the end of this project we will generate a diabetic mouse model with conditionally knocked out ACC1/2 in podocytes and proximal tubular epithelial cells which then will be ready to test its protective effect against DKD in downstream research.

Key facts

NIH application ID
10252084
Project number
1R56DK126647-01
Recipient
UNIVERSITY OF MICHIGAN AT ANN ARBOR
Principal Investigator
Farsad Afshinnia
Activity code
R56
Funding institute
NIH
Fiscal year
2020
Award amount
$101,400
Award type
1
Project period
2020-09-15 → 2022-11-30